newstodate.aero
Oct 29, 2020 (newstodate): COVAXX, a U.S. company developing a synthetic peptide-based vaccine to fight the COVID-19, has announced a global logistics partnership with Maersk.
Under the contract, Maersk with over 80,000 employees operating in 130 countries will support the mission by overseeing all logistics activities to ensure efficient transportation to developing countries.
The agreement provides for end-to-end supply chain management, packing and shipping by air or ocean, ground transportation, warehouse storage and distribution to facilities to support COVAXX’s requirements for a pharmaceutical grade, temperature-controlled supply chain.